Tuesday 21 May 2024 – Draft programme

Pre-conference workshops	
9.00am – 5.00pm	**ANDHealth Digital Summit**  *The full-day event will be packed with engaging leaders and feature keynote presentations, panel discussions, and networking opportunities. Throughout the event, industry experts will share real world evidence and lived experience to address the challenges in developing, commercialising and implementing cutting-edge digital and connected health technologies, products and services into global healthcare systems.* *The Summit will be attended by digital and connected health companies, industry professionals, service providers, investors and multinational medical device and pharmaceutical companies.*
8.30am – 12.30pm	**ASEAN regulatory requirements - addressing the practical issues** *The ASEAN region is an important market for Australian medical device companies for a variety of reasons, such as its proximity (example being physically closer to Australia than Europe), large market size (population of 600+ million), and increasing demand for improved standard of care and therefore medical devices.* *ASEAN medical device regulations are guided by the ASEAN Medical Device Directive, introduced about a decade ago* *In terms of regulatory approvals, ASEAN is different from European CE certification (CE Marking) process, with no version of CE Marking existing in the ASEAN region. Medical device companies need to seek regulatory approvals for each ASEAN country. The effort for medical device Regulatory Affairs team is not to be underestimated.* ***The objectives of this workshop are to:*** • *Gain an appreciation of ASEAN medical device regulations and the implementation across each country.* • *Get an update on current topics of interests on ASEAN medical device regulations.* • *Clarify questions you might have in your preparation for registering medical devices in the region. (Please provide your questions in advance via email).* • *Appreciation of the requirements for Good Distribution Practice Medical Devices (GDPMD). GDPMD has been and continues to be, rolled out across the ASEAN countries. GDPMD is a requirement for obtaining Import/wholesale/distribution license.*

1.00pm – 5.30pm	**AusMedtechInvest 2024** *AusMedtechInvest 2024 is Australia's inaugural boutique medtech investment roundtable forum, and aims to build meaningful personal connections between innovative medical technology (devices and diagnostic) businesses and investors, and help great ideas attract the capital needed to thrive in a fast-paced, competitive market.* 
1.30pm – 4.30pm	**AusMedtech South Australian Site Tours**    **Tour One: Adelaide BioMed City** **Tour time:** 1:30 pm – 4:30 pm **Check-in:** 1:00 pm – 1:30 pm **Meeting point:** Adelaide Convention Centre - AusMedtech Registration Area **Transport:** Walking tour **Tour Two: Lot Fourteen** **Tour Time:** 1.30 pm – 4.30pm **Check-in:** 1:00 pm – 1:30 pm **Meeting point:** Adelaide Convention Centre - AusMedtech Registration Area **Transport:** Walking tour and tram **Tour Three: Tonsley Innovation District** **Tour Time:** 1.30 pm – 4.30pm **Check-in:** 1:00 pm – 1:30 pm **Meeting point:** Adelaide Convention Centre - AusMedtech Registration Area **Transport:** Coach to Tonsley and returning to the Adelaide Convention Centre. Refreshments will be provided. **Tour Four: Mawson Lakes | Australian National Fabrication Facility – South Australia** **Tour Time:** 1.30 pm – 4.30pm **Check-in:** 1:00 pm – 1:30 pm **Meeting point:** Adelaide Convention Centre - AusMedtech Registration Area **Transport:** Coach and walking tour. Refreshments will be provided.

5.30pm -7.00pm	Pre-Conference welcome reception
	AusMedtech 2024 Welcome reception *Sponsored by:* FB RICE IP The IP Navigators
7.30pm	**Clinical trials dinner** *AusBiotech and its AusBiotech Clinical Trials Advisory Group warmly invite those working in the clinical trials sector to join them for this unsponsored, informal dinner and to connect face-to-face before AusMedtech 2024 conference officially begins.* *Clinical trials contribute to Australia economically and socially and are a critical component in the development process of bringing new therapies, devices and diagnostics to patients. However, the Australian clinical trial ecosystem is complex, involving many parts and stakeholders; this dinner is an opportunity to unite under the same roof and celebrate the sector and its progress.*

Wednesday 22 May 2024 – Draft programme

07.30am – 08.30am	**Delegate registration**
8.30am – 8.50am	**Opening & welcome**
	Conference opening and welcome address • **The Hon Susan Close MP,** Deputy Premier for South Australia, Minister for Industry, Innovation and Science, Minister for Climate, Environment and Water, and Minister for Defence and Space Industries • **Rosanne Hyland,** Acting Chief Executive Officer, AusBiotech
8.50am-9.15am	**Keynote session**
	National Health Medical Research Council (NHMRC) update **Chair: Gavin Fox-Smith**, Chief Executive Officer, Omnigon **Professor Steve Wesselingh**, Chief Executive Officer, National Health Medical Research Council *Further details to be confirmed*

9.15am – 10.00am	**Plenary session**
	Australian success stories *This panel discussion will celebrate the 2023/24 successful expansion and growth of medtech companies. Followed by a Q&A with the audience.* **Chair: Gavin Fox-Smith**, Chief Executive Officer, Omnigon **Panellists:** • **Sam Lanyon,** Executive Director, Lumos • **Marjan Mikel**, Chief Executive Officer & Managing Director, Respiri • *Further details to be confirmed*
10.00am – 10.25am	**Keynote session**
	Medical device regulation: an update on the latest *With sweeping reforms occurring across the globe in medical device regulation, this session focuses on how the Therapeutic Goods Administration (TGA) is supporting the industry through these changes, along with the challenges of regulating new and emerging technologies and what this means for Australian patients.* **Chair: Karen Parr,** Director Policy & Communications, AusBiotech **Professor Anthony Lawler**, Deputy Secretary, Medical Devices & Product Quality Division, Therapeutic Goods Administration
10.25am – 10.55am	Morning tea in the exhibition
10.55am- 11.55am	Plenary session
	Harnessing the pipeline: Partnering with big medtech *For medtech companies commercialising biomedical research across the ecosystem, there is an interdependent relationship between small and large companies. Multinational companies are a critical part of the Australian landscape, with their ability to provide the resources, experience, and infrastructure necessary to support R&D, clinical development, manufacturing, and distribution of devices and diagnostics.* *This plenary session provides an invaluable opportunity to hear from big medtech on partnering, prospecting, and support work in the Australian environment.* **Chair: Dell Kingsford Smith**, AusBiotech Board; Vice President Medical Affairs, Market Access & Government Affairs, Asia Pacific, Cochlear **Panellists:** • **Maurice Ben-Mayor**, President & Managing Director, Stryker • **Mick Trevaskis**, Chief Executive Officer, Device Technologies • **Rebecca Cortiula**, Senior Managing Director Australasia, Varian • **Jane Crowe**, Managing Director, ANZ Cardinal Health • **Pat Williams,** Vice President & Country Manager ANZ & Korea, Edwards Lifesciences
11.55am – 12.00pm	**Room move break**

Concurrent Sessions			
12.00pm – 12.55pm	**Session A**	**Session B**	**Session C**
	How to navigate MDR, why is the EU different now? *Europe continues to face a dynamic and challenging regulatory environment. In effect since 26 May 2021, the European Union's (EU) medical device (and In-Vitro Device Regulation (IVDR)) regulations mandate that medical device manufacturers targeting the EU market must adhere to new standards.* *Key changes introduced by these regulations include:* • *New requirements for translations* • *Stricter clinical evaluation and post-market surveillance* • *Expanded product scope* • *Introduction of unique device identification (UDI) systems* • *Greater transparency and data reporting* • *Reinforced patient safety measures, and* • *Enhanced role of notified bodies* *This panel of seasoned experts will discuss the issues facing the sector and pitfalls new players often come across.* **Chair: George Loizou**, Director, CMS SciDoc Pty Ltd **Panellists:** • **Julie Winson**, Quality and Regulatory Director, LBT Innovations • **Anthony Skeats**, Chief Operating Officer, Micro-X • **Chris Henry**, Managing Director, Actis Medical • **Hwee EE Tan**, Principal Consultant, DH RegSys Consulting Pty Ltd	**Building workforce skills and capabilities for successful medical device commercialisation** *In this session facilitated by ARCS Australia, the focus is on workforce skills and capabilities crucial for the effective commercialisation of medical devices. The session will feature representatives from industry, academia, and government perspectives to provide cross sector insights. Facilitated discussions will emphasise cross-sector collaborations, aiming to empower attendees with actionable insights for navigating the intricate landscape of medical device commercialisation. This session aspires to foster collaboration and skill enhancement, ensuring successful market entry for medical innovations.* **Chair: Dr Tim Boyle,** Chief Executive Officer, ARCS **Panellists:** • **Dana Bell**, Director Partnership SA, MTPConnect • **Shan-Shan Wang**, Founder & Chief Executive Officer, Roam Engineering • **Ajay Nair,** President APAC, Mullings Group *Further speakers to be confirmed* *In partnership with:* 	**Capital markets: is the 'old normal' actually the 'new normal'?** *After almost 2 years of steep declines in valuation, many industry players are talking about a "return to normal". But were the heady days of no-low due diligence, FOMO driven investments and "frothy" valuations really normality? Or are we just longing for a moment in time to return?* **Chair: Bronwyn Le Grice,** Managing Director & Chief Executive Officer, ANDHealth **Panellists:** • **Dr Chris Nave**, Founding Partner & Managing Director, Brandon Capital • **Dr Amanda Gillon**, Senior Partner, BioScience Managers • **Dr Steve Burnell,** Managing Director, TenMile • *Further speakers to be confirmed*
12.55pm - 1.55pm	Lunch in the exhibition		

Concurrent sessions			
1.55pm 2.50pm	**Session D**	**Session E**	**Early-Stage Innovation Forum**
	Ethics and AI – has the horse already left the stable? *Artificial intelligence has been heralded as the largest technological change facing our generation, but concerns about ethics, privacy and consumer protection are still front of mind. As the Australian Government contemplates regulation of AI, we have to consider whether this might be a case of shutting the stable door after the horse has bolted.* **Chair: Grace Lethlean,** Chief Product Officer, ANDHealth **Panellists:** • **Daniela Cecere-Palazzo,** Senior Lawyer, Youlegal • **Angie Corbo**, Informatics Global Catalyst Innovation & Architecture, Roche • *Further speakers to be confirmed* *In partnership with:* ANDHealth Australia's National Digital Health Initiative	**Demystifying federal funding programs** *Set yourself up for funding success by learning about the suite of programmes funded by the Federal Government that support medtech innovation. Hear about the purpose and intention of each programme, eligibility criteria, who they are best suited for, the type of projects they are looking to support, and upcoming dates.* **Chair: Dr Tracey Wilkinson**, Director Stakeholder Engagement WA, MTPConnect **Panellists:** • **Associate Professor Tracey Laba**, Director Frontiers Program, Medical Research Future Fund, Dept of Health & Aged Care • **Representative,** National Reconstruction Fund • *Further speakers to be confirmed*	*The Early-Stage Innovation Forum, will feature rapid fire rounds of quick-pitch presentations on early-stage technologies and projects from local research institutes, universities, hospitals and pre-series A companies in the areas of medical devices and diagnostics, digital health and enabling technologies.*
2.50pm– 3.45pm	**Session F**	**Session G**	**Early-Stage Innovation Forum**
	Making market access a priority for Australian Innovators *In 2017 the OECD released a report detailing that "public procurement offers an enormous potential market for innovative products and services. Used strategically, it can help governments boost innovation at both the national and local level and ultimately improve productivity and inclusiveness." In Australia it could be argued that this has not been the case and the Australian response to the COVID19 pandemic is emblematic of this attitude in our*	**The growing importance of environmental, social, and governance (ESG) and how does the medtech board react to this?** *The Boston Consulting Group states "Health care accounts for 5% of total global carbon emissions, and medical devices and technology are responsible for a large portion of that. Much of this comes from the manufacturing operations and supply chains of medtech companies and their suppliers. At the provider level, medtech generates tonnes of unrecycled waste through single-use disposable products and packaging."*	

	healthcare system in particular. Issues that could be driving this attitude could include such factors as risk aversion, management, personnel and skills capacity and political support. *This experienced panel will discuss possible solutions such as policy strategies with defined targets, sufficient budgets, funds and other financial incentives, build staff capabilities and skills, setting up multidisciplinary teams and competence centres focused on public procurement for innovation.* **Chair: Tracey Shearer**, Managing Director, August Consulting **Panellists:** • **Professor Tracy Merlin,** Deputy Executive Dean, Faculty of Health and Medical Sciences Head, School of Public Health, University of Adelaide • **Andrea Andrews**, Executive Director Procurement and Supply Chain Management, SA Health • *Further speakers to be confirmed*	*There is a growing demand from customers, shareholders and employees for Boards to implement ESG initiatives within organisations. Medtech companies must choose to balance current competitiveness and future investments while connecting ESG to economic value. This panel of experienced executives and Board members will tackle the thorny issue of how to do this whilst generating value.* **Chair: Melissa McBurnie**, Partner & Head of Impact, Brandon Capital **Panellists:** • **Lusia Guthrie**, Chair, Neo-Bionica • *Further speakers to be confirmed*	
3.45pm–4.15pm	Afternoon tea in the exhibition		
Concurrent sessions			
4.15pm–5.10pm	**Session H**	**Session I**	**Early-Stage Innovation Forum**
	Reimbursement *Are Australia's medtech reimbursement pathways appropriately designed and sufficiently rewarding to attract both local and global innovation?* **Chair:** *to be confirmed* **Panellists:** • *Speakers to be confirmed*	**Beyond patents: strategic use of all your intangible assets and how not to kill a deal** *Our panel will discuss the often-untapped value that sits within a corporate's intellectual property (IP) and provide tips to identify, grow, and maximise the value of these assets. As well as a focus on building one's own IP and market exclusivity, the panel will also discuss the importance of understanding the IP held by others and the resultant freedom to operate in key markets.* **Chair: Rachel Hooke,** Partner, FB Rice	

		Panellists: • **Anna Smyth**, Partner, Gilbert and Tobin • **Derek Minihane**, Partner, Deloitte • *Further speakers to be confirmed*	
7.00pm– 7.30pm	Pre-dinner drinks		
7.30pm – 10.00pm	**AusMedtech conference dinner** **Rosanne Hyland**, Acting Chief Executive Officer, AusBiotech **Dinner speakers: Scott Stirling**, Chief Executive Officer & **Jonathon Lindsay-Tjapaltjarri Hermawan**, Director of Programs and Strategy Lead, Red Dust **Facilitator:** to be confirmed *With Australia's indigenous communities overrepresented in low socioeconomic figures, Australia's First Nations people face a greater risk of poor health, higher rates of illness, disability, and death, and live shorter lives than people from higher socioeconomic groups.* *Founded in the Northern Territory, not-for-profit Red Dust draws on the strengths of both western health knowledge and traditional cultural knowledges to create a positive influence on young people and improve outcomes for communities. Providing a 'community-as-family' model of health and well-being programmes, Red Dust works alongside community leaders and elders to create a stronger future for indigenous youth and their families.* *Join us for a fireside chat with Red Dust founders, Pintupi man Jonathan Hermawan and CEO Scott Stirling, as they discuss their personal journey over the past seven years growing Red Dust and developing a cooperative model that is charting a new course and leading to improved health and wellbeing outcomes.*	



Thursday 23 May 2024 – Draft programme

8.30am – 9.00am	Delegate registration
9.00am – 10.00am	**Plenary session**
	Issues facing healthcare in Australia *Get your caffeine fix from the exhibition hall and start day 2 of the conference with a wide-ranging panel discussion with leaders from our representative industry and government organisations about the burning challenges- and the exciting opportunities- facing the Australian healthcare sector that are keeping them awake at night.* **Chair: Stuart Dignam,** Chief Executive Officer, MTPConnect **Panellists:** • **Ian Burgess,** Chief Executive Officer, MTAA • **Dr Anna Lavelle,** Chair, Medicines Australia • **Dr Tim Boyle,** Chief Executive Officer, ARCS • **AusBiotech,** Chief Executive Officer
10.00am – 10.30am	**Keynote session**
	What women don't want *Much is made about the progress of corporate Australia in the diversity stakes, however 2023 saw some disturbing stories about women in corporate Australia sitting on the receiving end of verbal and physical harassment and abuse. The digital harassment of women leaders is now a frequent occurrence for women in politics and advocacy, academia, media, and private industry, with insults, abuse, threats, trolling and doxing now a commonplace for women leaders.*

	A play on the 2000 film What Women Want, this panel will reflect on their personal experiences as they shine a spotlight on the treatment of professional women, and challenge industry to become champions of change in ending discrimination against women in the workplace. **Chair: Bronwyn Le Grice,** Managing Director & Chief Executive Officer, ANDHealth • **Rebecca Wilson**, Chair, Alcidion • **Dr Elaine Stead,** Founder, Human VC • **Michelle Gallagher**, Chief Executive Officer, Cerulea		
10.30am – 11.00am	Morning tea in the exhibition		
11.00am – 11.55am	**Session J**	**Session K**	**Session L**
	AI in medical imaging – from promise to practice *The promise of artificial intelligence (AI) in medical imaging analysis has been discussed for many years and is now a reality. Was it smooth sailing for this seemingly ideal use case? Are there lessons to be shared which will inform the next wave of technologies? In this panel discussion we'll hear from those who have been at the forefront of the development and adoption of AI in medical imaging, they'll share what's worked, what didn't, the challenges that remain and where to next.* **Chair: Dr Ludovic Labat,** Chief Executive Officer, Neo-Bionica **Panellists:** • **Dr Michelle Perugini**, Chief Executive Officer, Presagen **Mark Phillips**, Head of Clinical Research & Medical Affairs, Annalise.ai • **Dr Wenji Pang**, Chief Scientific Officer - Imaging & AI, Resonance Health • **Alison Deslandes,** President, Australasian Society of Ultrasound in Medicine	**Exploring the emerging material science manufacturing and investment opportunities to reduce medical plastic waste** *Hospital generated plastic waste is a worldwide issue. When first introduced into hospitals, single-use plastics were an attractive option as it allowed for maintenance of a sterile environment and infected plastic material could be easily disposed via landfill waste. For equipment such as syringes this is vital. However, the sheer quantity of single use plastics being used in hospitals is becoming alarming, particularly considering the overuse or unnecessary use of single-use plastics.* *In Australia, the healthcare industry is responsible for around 8% of Australia's carbon emissions and generates large amounts of non-recyclable plastic waste. Environmental Social Governance (ESG) factors are increasingly becoming a factor in procurement and related commercial decisions.* *This diverse panel session will discuss ways to address these issues and funding assistance that is available*. **Chair: Stuart Anderson,** Clinical Translation and Commercialisation Medtech Program Manager, MTAA **Panellists:** • **Jane Crowe**, Managing Director, ANZ Cardinal Health • *Further speakers to be confirmed*	**Partnering - the pathway to success...or is it?** *A business partnership is a collaboration between two or more entities that pool resources, technology and/or finances to achieve a generally agreed goal. In Medtech this is a widely accepted pathway to develop technology, access markets or ensure access to specific technologies. Whilst there are many instances of this being a success there are also many instances where the expected success did not materialise. This panel of seasoned executives will discuss many of the pitfalls and key decision points where partnerships are useful of inhibitory.* **Chair: Peter Bradley,** Principal, Qatalyst Consulting **Panellists:** • **Peter Rowland**, Non-Executive Director, Micro-X • **Michael Kavanagh,** Chief Executive Officer & President, Nanosonics • **Dr Anabela Correia,** Chief Executive Officer, LiVac • *Further speakers to be confirmed*

		In partnership with: 	
11.55am – 12.50pm	**Session M**	**Session N**	**Session O**
	Strategic considerations in manufacturing for medtech *With a strong push and incentives for sovereign and local manufacturing capacity, how might medtech companies think about whether to buy, build or partner to develop the capabilities, skillsets and tools required to execute on manufacturing at scale. This session will explore the strategic thinking required for manufacturing business decisions, including the impact of technologies such as additive manufacturing, Industry 4.0, robotics, AI and other emerging technologies.* **Chair: Nick Northcott,** Managing Partner, Chrysalis Advisory **Panellists:** • **Lisa Henretty**, Chief Operating Officer, Enersol • **Louisa De Vries**, Consulting Manager, Bosch Australia Manufacturing Solutions • **Val Valentine,** Director, Edwards Lifesciences • *Further speakers to be confirmed*	**What angel investors look for in a medtech startup company** *Many early-stage companies require external funding. One source of funding can come from Angel Investors, who typically provide a cash injection in exchange for equity in the company. Startups, particularly in the medtech sector, can be a risky proposition for an investor, and there are key elements that an Angel Investor will look for when deciding whether to invest in that company. Such considerations may include the strength of the team behind the startup, the business model, what intellectual property the startup has, and ultimately, what sort of return the Angel Investor can obtain on their investment.* *This panel session, which comprises Angel Investors who are active in investing in startups in the MedTech industry, will discuss the key elements that they look for in a startup when deciding whether or not to invest, and provide insight into how you, as a startup, can best position yourself so as to make yourself as attractive to an Angel Investor as possible. Some of the panel members have also been in the position of forming a startup and themselves seeking investment, and can provide valuable advice from their own experiences.* *The session will be chaired by Dr Milena Dryza, Senior Associate of Madderns Patent and Trade Mark Attorneys. Milena is a patent attorney with many years of experience in private practice, as well as an in-house patent counsel for leading biotechnology company, CSL.* **Chair: Dr Milena Dryza** Senior Associate, Madderns Patent	**Optimising clinical trial delivery** *As an early stage medtech company or founder it is often difficult to know exactly what is required to get a product/asset through the clinical phase. This session will explore the things you need to consider when running a clinical trial and before you start writing the protocol. You have a product, you know what you want it to do, you've even got it to the point it's ready for clinical testing and met all the manufacturing regulatory requirements. But wait, clinical research has its own regulatory standards and requirements. How on earth do I navigate this world? The panel will discuss the considerations for embarking on the clinical development phase of a trial, when you should start to plan, what to look out for, whether to hire or contract expertise and how to engage a site(s) and clinician(s).* **Chair: Natalie Barber**, Director, Clinical Operations, Chrysalis **Panellists:** • **Simon Cook**, Executive Director, Operations, Eudaemon Technologies • *Further speakers to be confirmed*

		& Trademark Attorneys. **Panellists:** • **Dr Anabela Correia**, Chief Executive Officer, LiVac • **Dr Nick Haan,** Chief Executive Officer. Seonix Bio • **Josh Garratt,** Executive Officer, Southern Angels • *Further speakers to be confirmed* *Sponsored by:* maddecns	
12.50pm – 1.45pm	**Session P**	**Session Q**	**Session R**
	What infrastructure do we need to build a vibrant medtech innovation and commercialisation ecosystem *The road to successful commercialisation in medtech is often winding and with many obstacles along the way. Being aware of the pitfalls and shaping your start-up for the best possible outcome is no simple task. It has been said we need the right people, science, infrastructure and money to build a success. Incubator and accelerator programmes are a vital part of the medtech innovation ecosystem but what else is required to help our sector? and provide a rich environment of education, mentorship, industry collaboration, networking and capital raising support. Our panel will look into the roles of education, mentorship, industry collaboration, networking and capital raising support. Where are the gaps and how do we fill them?* **Chair: Professor Karen Reynolds,** Director, Medical Device Partnering Program **Panellists:** • **Dr Lilly Bojarski**, General Manager, Cicada Health Tech Hub • **Natalie Rickers**, Commercialisation Director, South Australia MTP Connect	**How to close a VC round (and retain your sanity)** *Competition for capital is fierce at the moment, with investors focusing on the stability of their existing portfolio and wary of cash burn in a tight market. So how DO you land a significant investor, and more importantly, what do you need to do to close the deal!* **Chair: Sarah Meibusch,** Partner, OneVentures **Panellists:** • **Arthur Shih**, Chief Executive Officer, Humanetix • **Peter Vranes,** Chief Executive Officer & Co-Founder, Nutromics • **Richard Horton,** Partner, Squire Patton Boggs • *Further speakers to be confirmed*	**Are medtech and digital product clinical trials - same or different?** *Following on from the previous panel session that explored how early stage medtech companies navigate the clinical phase, in this session the invited speakers explore more specifically the commonalities and differences in designing, running and managing clinical trials between digital products and devices, as well as digitally enabled devices.* *Founder will share how they navigated the sometimes-unclear requirements for Software as a Medical Device trials in both Australia and the US, and what they learned from the more established medical device trials. We also explore how to work with CROs, and how to assess who would be the right partner.* *The goal of the session is to get clarity on what common pitfalls are, and highlight relevant factors and strategies to accelerate the clinical phase for both devices and digital products.* **Chair: Dr Katja Beitat,** Head of Health Tech, Cicada Innovations

	• *Further speakers to be confirmed*		**Panellists:** • **Helen Souris**, Chief Executive Officer, CardiHub • **Mary-Beth Brinson**, Chief Executive Officer Cyban • **Stewart Bartlett,** Chief Executive Officer Ferronova • *Further speakers to be confirmed*
1.45pm – 2.45pm	Lunch in the exhibition		
2.45pm – 3.15pm	**Plenary session**		
	The 20-year journey: IDE Group's impact on the global medtech ecosystem **Chair: Warren Bingham**, Global Vice President, ARIA Research With a global presence and multidisciplinary skills, IDE Group is a well-regarded partner for medtech commercialisation and product development. IDE works with its partners to find and assess business opportunities, conduct research, create and implement commercial strategy, gain access to funding, develop new technology, manufacture quality products and create successful medtech ventures. Since 2003, IDE has grown over 150 medical technology businesses and realised over 500 projects across the medical technology landscape globally. In this fire side chat, hear from IDE Group CEO George Sidis as he discusses the organisation's journey to date and how it's supported Australian medtech innovators to generate high-impact and improve health outcomes. **George Sidis,** Chief Executive Officer, IDE Group		
3.15pm – 4.15pm	**Plenary session**		
	Take home lessons from AusMedtech 2024 **Chair: Peter Bradley,** Principal, Qatalyst Consulting The two days of AusMedtech are a cornucopia of data, information, knowledge, and wisdom. Many of us will have individual gems that are pertinent to our particular business or problem to take home. However, many of the big picture and relevant issues explored may be missed because of conflicts or competing priorities drawing attendees to other sessions. This panel of hardened Medtech executives have made it a mission to pick the pearls of wisdom from the conference and highlight to the final audience. We will also draw on the collective attendees to reduce these to actionable take home messages from the conference. **Panellists:** - **Jo Close,** Director Adelaide Intermediary Program, MTPConnect - *Further speakers to be confirmed*		

4.15pm – 5.00pm	**Conference closing reception** Exhibition Hall
	Rosanne Hyland, Acting Chief Executive Officer, AusBiotech